Skip to main content

MECANISMOS DE RESISTENCIA ADQUIRIDA A SORAFENIB EN EL CARCINOMA HEPATOCELULAR

BES-2017-081286

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

  • Cappuyns, Sarah
  • Piqué-Gili, Marta
  • Esteban-Fabró, Roger
  • Philips, Gino
  • Balaseviciute, Ugne
  • Pinyol, Roser|||0000-0002-0288-6314
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Vandecaveye, Vincent
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Montironi, Carla|||0000-0002-1453-2193
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Peix, Judit
  • Zeitlhoefler, Marcus
  • Mesropian, Agavni
  • Huguet Pradell, Júlia
  • Haber, Philipp K
  • Figueiredo, Igor
  • Ioannou, Giorgio
  • Gonzalez Kozlova, Edgar
  • D'Alessio, Antonio
  • Mohr, Raphael
  • Meyer, Tim
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Marquardt, Jens U
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Edeline, Julien
  • Finkelmeier, Fabian
  • Trojan, Jorg
  • Galle, Peter R
  • Foerster, Friedrich
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Montal, Robert
  • Gnjatic, Sacha
  • Pinato, David James|||0000-0002-3529-0103
  • Heikenwälder, Mathias
  • Verslype, Chris
  • Van Cutsem, Eric|||0000-0002-6372-1230
  • Lambrechts, Diether
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Dekervel, Jeroen
  • Llovet, Josep M.|||0000-0003-0547-2667
The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit vs. resistance to atezo+bev. We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of patients with advanced HCC treated with atezo+bev (n = 317) vs. atezolizumab (n = 47) or sorafenib (n = 58) as comparators. We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterised by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune-rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs. sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define " Immune-competent " and " Angiogenesis-driven " molecular subgroups, each associated with a significantly longer OS with atezo+bev vs. sorafenib (p of interaction = 0.027), and a " Resistant" subset. Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC (" Immune-competent" and " Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance. Atezolizumab + bevacizumab (atezo+bev) is standard of care in advanced hepatocellular carcinoma (HCC), yet molecular determinants of clinical benefit to the combination remain unclear. This study harnesses the power of single-cell RNA sequencing, deriving gene expression signatures representing 21 cell subtypes in the advanced HCC microenvironment. By applying these signatures to RNA-sequencing samples, we reveal two distinct response patterns to atezo+bev and define molecular subgroups of patients (" Immune-competent" and " Angiogenesis-driven" vs. "Resistant") with differential clinical outcomes upon treatment with atezo+bev, pointing towards the role of immunosuppressive myeloid cell types and Notch pathway activation in primary resistance to atezo+bev. These results may help refine treatment strategies and improve outcomes for patients with advanced HCC, while also guiding future research aimed at overcoming resistance mechanisms.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma, implications for biomarker-driven clinical trials

  • Montal, Robert
  • Andreu-Oller, Carmen|||0000-0001-7405-9134
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Esteban-Fabró, Roger
  • Moran, S.|||0000-0003-4192-8983
  • Montironi, Carla|||0000-0002-1453-2193
  • Moeini, Agrin
  • Pinyol, Roser|||0000-0002-0288-6314
  • Peix, Judit
  • Cabellos, Laia
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Sia, Daniela|||0000-0002-9000-611X
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
  • Esteller, M.|||0000-0003-4490-6093
  • Llovet, Josep M.|||0000-0003-0547-2667
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PCIG, a web-based application to explore immune-genomics interactions across cancer types

  • Pedrola Gómez, Anna|||0000-0002-0490-3851
  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Lahoz, Sara|||0000-0002-4491-9911
  • Esteban-Fabró, Roger
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Camps Polo, Jordi|||0000-0003-2929-4228
Genomic alterations can modulate the tumor immunophenotype depending on their nature and tissue of origin. Although this immune-genomic interaction may shape disease progression and response to immunotherapy, the factors governing such dynamics and the influence of each tissue-specific context remain poorly understood. Here, we have developed the PanCancer ImmunoGenomics (PCIG) tool, a web-based resource that provides researchers with the opportunity to mine immunome-genome relationships across several cancer types using data from the Pan-Cancer Analysis of Whole-Genomes (PCAWG) study, which comprises.